ONCOSIL MEDICAL LTD - Announcements

Market Cap $49.19M Add to my watchlist

Technology Scientific & Technical Instruments

OncoSil Medical Ltd is an Australia-based medical device company focused on localized... OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.More

BlinkLab Limited (ASX: BB1) is a trailblazer in digital healthcare, leveraging AI and machine learning in mobile applications to revolutioniSe neurodevelopmental condition diagnosis like ASD and ADHD. Born from extensive research at Princeton University,...

Announcements

Filter Results

All Price Sensitive Only

OSL	OncoSil Launches $10m Capital Raising	PRICE SENSITIVE	29/04/22	282.3KB	Share
OSL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	867.87KB	Share
OSL	OncoSil Signs Commercial Agreement With Hospital In Spain	PRICE SENSITIVE	29/04/22	220.58KB	Share
OSL	Trading Halt	PRICE SENSITIVE	27/04/22	207.12KB	Share
OSL	First Commerical Pancreas Treatment In Spain	PRICE SENSITIVE	13/04/22	214.12KB	Share
OSL	Fully-Funded Trial Approved In Germany	PRICE SENSITIVE	28/03/22	218.59KB	Share
OSL	Half Yearly Report Results	PRICE SENSITIVE	22/02/22	283.27KB	Share
OSL	Half Yearly Report and Accounts	PRICE SENSITIVE	22/02/22	674.09KB	Share
OSL	OncoSil approved for Innovation Funding (NUB) in Germany	PRICE SENSITIVE	03/02/22	211.91KB	Share
OSL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/22	478.63KB	Share
OSL	PanCO Clinical Study on OncoSil Published in ESMO Open	PRICE SENSITIVE	24/12/21	267.36KB	Share
OSL	Initial Director's Interest Notice - Prof. Ricky Sharma		01/11/21	380.21KB	Share
OSL	Jobkeeper Payments Notification		01/11/21	217.45KB	Share
OSL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/10/21	476.61KB	Share
OSL	Change of Director's Interest Notice - Mr Nigel Lange		20/10/21	234.36KB	Share
OSL	Final Director's Interest Notice - Mr Michael Bassett		20/10/21	233.38KB	Share
OSL	Final Director's Interest Notice - Dr Chris Roberts		20/10/21	235.79KB	Share
OSL	Notification regarding unquoted securities - OSL		20/10/21	26.51KB	Share
OSL	Issue of Performance Rights		20/10/21	212.88KB	Share
OSL	Final Director's Interest Notice		19/10/21	221.11KB	Share
OSL	Results of the OncoSil 2021 Annual General Meeting		19/10/21	186.18KB	Share
OSL	2021 AGM CEO Presentation	PRICE SENSITIVE	19/10/21	802.36KB	Share
OSL	2021 AGM Chairman's Address	PRICE SENSITIVE	19/10/21	315.98KB	Share
OSL	Resignation of Director - Dr Roger Aston		19/10/21	232.67KB	Share
OSL	Prof. Ricky Sharma appointed to the Board of OncoSil		12/10/21	246.9KB	Share
OSL	Receipt of $1.077m R&D Tax Incentive Refund	PRICE SENSITIVE	27/09/21	203.32KB	Share
OSL	Notice of General Meeting/Proxy Form		17/09/21	1.69MB	Share
OSL	Change of Director's Interest Notice		25/08/21	233.09KB	Share
OSL	Appendix 4G and Corporate Governance Statement		19/08/21	604.41KB	Share
OSL	Appendix 4E Announcement	PRICE SENSITIVE	19/08/21	284.85KB	Share
OSL	Appendix 4E and Annual Report	PRICE SENSITIVE	19/08/21	1.13MB	Share
OSL	Cancellation of shares under the Employee Share Plan		11/08/21	207.52KB	Share
OSL	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/07/21	496.52KB	Share
OSL	Initial Director's Interest Notice		21/07/21	188.39KB	Share
OSL	Otto Buttula appointed to the Board of OncoSil		20/07/21	257.7KB	Share
OSL	OncoSil TGA regulatory update	PRICE SENSITIVE	02/06/21	255.86KB	Share
OSL	Cancellation of loan funded shares		10/05/21	212.76KB	Share
OSL	Change of Director's Interest Notice		10/05/21	185.86KB	Share
OSL	OncoSil receives regulatory approval from Hong Kong	PRICE SENSITIVE	04/05/21	215.63KB	Share
OSL	Appendix 4C - quarterly	PRICE SENSITIVE	29/04/21	492.86KB	Share
OSL	Change of Registered Office and Principal Place of Business		01/03/21	141.32KB	Share
OSL	Business update call transcript		26/02/21	287.63KB	Share
OSL	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/21	415.31KB	Share
OSL	Half-Yearly Report Results	PRICE SENSITIVE	23/02/21	290.47KB	Share
OSL	OncoSil Investor Update	PRICE SENSITIVE	18/02/21	1.15MB	Share
OSL	Business Update - Conference Call Notification		16/02/21	223.59KB	Share
OSL	Appointment of Chief Medical Officer & Medical Affairs Head		10/02/21	252.73KB	Share
OSL	Appendix 4C - quarterly	PRICE SENSITIVE	28/01/21	491.37KB	Share
OSL	Cancellation of shares under the Employee Share Plan		28/01/21	214.56KB	Share
OSL	Initial Director's Interest Notice		21/01/21	187.08KB	Share
OSL	Appointment of Chief Executive Officer	PRICE SENSITIVE	21/01/21	273.13KB	Share
OSL	OncoSil FY21 half yearly review	PRICE SENSITIVE	18/01/21	245.86KB	Share
OSL	Final Director's Interest Notice		18/12/20	220.98KB	Share
OSL	Change of Director's Interest Notice		18/12/20	233.98KB	Share
OSL	Change of Director's Interest Notice		18/12/20	233.95KB	Share
OSL	Cancellation of shares under the Employee Share Plan		18/12/20	212.92KB	Share
OSL	Termination of Mr Daniel Kenny as Chief Executive Officer	PRICE SENSITIVE	02/12/20	210.14KB	Share
OSL	Change of Director's Interest Notice		05/11/20	233.98KB	Share
OSL	Appendix 2A		05/11/20	394.89KB	Share
OSL	OncoSil receives Swiss regulatory approval	PRICE SENSITIVE	05/11/20	220.13KB	Share
OSL	Change of Director's Interest Notice		29/10/20	234.58KB	Share
OSL	Change of Director's Interest Notice		27/10/20	232.99KB	Share
OSL	OncoSil achieves first commercial sale	PRICE SENSITIVE	22/10/20	302.82KB	Share
OSL	Appendix 4C - quarterly	PRICE SENSITIVE	21/10/20	506.86KB	Share
OSL	Results of the OncoSil 2020 Annual General Meeting		20/10/20	294.36KB	Share
OSL	Positive PanCO trial update on resected cohort	PRICE SENSITIVE	20/10/20	319.8KB	Share
OSL	2020 AGM CEO Presentation	PRICE SENSITIVE	20/10/20	984.59KB	Share
OSL	2020 AGM Chairman's Address		20/10/20	171.13KB	Share
OSL	Receipt of $2.8m R&D Tax Incentive Refund	PRICE SENSITIVE	23/09/20	208.4KB	Share
OSL	2020 Notice of General Meeting & Proxy Form		18/09/20	1.02MB	Share
OSL	Investor Update	PRICE SENSITIVE	28/08/20	1.34MB	Share
OSL	Investor Update - Conference Call Notification		28/08/20	214.51KB	Share
OSL	OncoSil receives Malaysian regulatory approval	PRICE SENSITIVE	28/08/20	264.36KB	Share
OSL	Appendix 4G and Corporate Governance Statement		19/08/20	334.8KB	Share
OSL	Preliminary Final Report - Appendix 4E Announcement	PRICE SENSITIVE	19/08/20	286.58KB	Share
OSL	Appendix 4E and Annual Report	PRICE SENSITIVE	19/08/20	3.13MB	Share
OSL	Clarification of June Quarter Appendix 4C		07/08/20	151.35KB	Share
OSL	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/20	507.9KB	Share
OSL	HDE filing submitted in US for Bile Duct Cancer treatment	PRICE SENSITIVE	28/07/20	215.69KB	Share
OSL	OncoSil presents clinical data at ESMO World Congress	PRICE SENSITIVE	03/07/20	538.69KB	Share
OSL	OncoSil files for TGA registration	PRICE SENSITIVE	02/07/20	221.05KB	Share
OSL	Change of Director's Interest Notice		30/06/20	123.55KB	Share
OSL	Change of Director's Interest Notice		30/06/20	233.23KB	Share
OSL	Cancellation of shares under the Employee Share Plan		30/06/20	204.79KB	Share
OSL	OncoSil receives Singapore regulatory approval	PRICE SENSITIVE	01/06/20	258.23KB	Share
OSL	Change of Directors Interest Notice		29/05/20	233.04KB	Share
OSL	Change of Director's Interest Notice - Roger Aston		29/05/20	233.02KB	Share
OSL	Change of Director's Interest Notice - Michael Bassett		29/05/20	233.81KB	Share
OSL	Change of Director's Interest Notice - Martin Cross		29/05/20	232.94KB	Share
OSL	Change in substantial holding - Daniel Kenny		29/05/20	233.04KB	Share
OSL	Change of Director's Interest Notice - Chris Roberts		29/05/20	235.34KB	Share
OSL	Appendix 3Y - Late Lodgement Notice - Roger Aston		29/05/20	571.4KB	Share
OSL	Appendix 3Y - Late Lodgement Notice - Daniel Kenny		29/05/20	395.49KB	Share
OSL	Appendix 2A		28/05/20	269.08KB	Share
OSL	Ceasing to be a substantial holder		26/05/20	44.89KB	Share
OSL	Entitlement Offer Results and Shortfall Notification	PRICE SENSITIVE	26/05/20	216.89KB	Share
OSL	Ceasing to be a substantial holder		19/05/20	573.86KB	Share
OSL	Becoming a substantial holder		13/05/20	335.63KB	Share
OSL	Becoming a substantial holder		12/05/20	83.1KB	Share
OSL	OncoSil Entitlement Offer Booklet	PRICE SENSITIVE	12/05/20	503.35KB	Share

OSL OncoSil Launches $10m Capital Raising
29/04/22	PRICE SENSITIVE	282.3KB	Share
OSL Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	867.87KB	Share
OSL OncoSil Signs Commercial Agreement With Hospital In Spain
29/04/22	PRICE SENSITIVE	220.58KB	Share
OSL Trading Halt
27/04/22	PRICE SENSITIVE	207.12KB	Share
OSL First Commerical Pancreas Treatment In Spain
13/04/22	PRICE SENSITIVE	214.12KB	Share
OSL Fully-Funded Trial Approved In Germany
28/03/22	PRICE SENSITIVE	218.59KB	Share
OSL Half Yearly Report Results
22/02/22	PRICE SENSITIVE	283.27KB	Share
OSL Half Yearly Report and Accounts
22/02/22	PRICE SENSITIVE	674.09KB	Share
OSL OncoSil approved for Innovation Funding (NUB) in Germany
03/02/22	PRICE SENSITIVE	211.91KB	Share
OSL Quarterly Activities/Appendix 4C Cash Flow Report
31/01/22	PRICE SENSITIVE	478.63KB	Share
OSL PanCO Clinical Study on OncoSil Published in ESMO Open
24/12/21	PRICE SENSITIVE	267.36KB	Share
OSL Initial Director's Interest Notice - Prof. Ricky Sharma
01/11/21		380.21KB	Share
OSL Jobkeeper Payments Notification
01/11/21		217.45KB	Share
OSL Quarterly Activities/Appendix 4C Cash Flow Report
29/10/21	PRICE SENSITIVE	476.61KB	Share
OSL Change of Director's Interest Notice - Mr Nigel Lange
20/10/21		234.36KB	Share
OSL Final Director's Interest Notice - Mr Michael Bassett
20/10/21		233.38KB	Share
OSL Final Director's Interest Notice - Dr Chris Roberts
20/10/21		235.79KB	Share
OSL Notification regarding unquoted securities - OSL
20/10/21		26.51KB	Share
OSL Issue of Performance Rights
20/10/21		212.88KB	Share
OSL Final Director's Interest Notice
19/10/21		221.11KB	Share
OSL Results of the OncoSil 2021 Annual General Meeting
19/10/21		186.18KB	Share
OSL 2021 AGM CEO Presentation
19/10/21	PRICE SENSITIVE	802.36KB	Share
OSL 2021 AGM Chairman's Address
19/10/21	PRICE SENSITIVE	315.98KB	Share
OSL Resignation of Director - Dr Roger Aston
19/10/21		232.67KB	Share
OSL Prof. Ricky Sharma appointed to the Board of OncoSil
12/10/21		246.9KB	Share
OSL Receipt of $1.077m R&D Tax Incentive Refund
27/09/21	PRICE SENSITIVE	203.32KB	Share
OSL Notice of General Meeting/Proxy Form
17/09/21		1.69MB	Share
OSL Change of Director's Interest Notice
25/08/21		233.09KB	Share
OSL Appendix 4G and Corporate Governance Statement
19/08/21		604.41KB	Share
OSL Appendix 4E Announcement
19/08/21	PRICE SENSITIVE	284.85KB	Share
OSL Appendix 4E and Annual Report
19/08/21	PRICE SENSITIVE	1.13MB	Share
OSL Cancellation of shares under the Employee Share Plan
11/08/21		207.52KB	Share
OSL Quarterly Activities/Appendix 4C Cash Flow Report
26/07/21	PRICE SENSITIVE	496.52KB	Share
OSL Initial Director's Interest Notice
21/07/21		188.39KB	Share
OSL Otto Buttula appointed to the Board of OncoSil
20/07/21		257.7KB	Share
OSL OncoSil TGA regulatory update
02/06/21	PRICE SENSITIVE	255.86KB	Share
OSL Cancellation of loan funded shares
10/05/21		212.76KB	Share
OSL Change of Director's Interest Notice
10/05/21		185.86KB	Share
OSL OncoSil receives regulatory approval from Hong Kong
04/05/21	PRICE SENSITIVE	215.63KB	Share
OSL Appendix 4C - quarterly
29/04/21	PRICE SENSITIVE	492.86KB	Share
OSL Change of Registered Office and Principal Place of Business
01/03/21		141.32KB	Share
OSL Business update call transcript
26/02/21		287.63KB	Share
OSL Half Yearly Report and Accounts
23/02/21	PRICE SENSITIVE	415.31KB	Share
OSL Half-Yearly Report Results
23/02/21	PRICE SENSITIVE	290.47KB	Share
OSL OncoSil Investor Update
18/02/21	PRICE SENSITIVE	1.15MB	Share
OSL Business Update - Conference Call Notification
16/02/21		223.59KB	Share
OSL Appointment of Chief Medical Officer & Medical Affairs Head
10/02/21		252.73KB	Share
OSL Appendix 4C - quarterly
28/01/21	PRICE SENSITIVE	491.37KB	Share
OSL Cancellation of shares under the Employee Share Plan
28/01/21		214.56KB	Share
OSL Initial Director's Interest Notice
21/01/21		187.08KB	Share
OSL Appointment of Chief Executive Officer
21/01/21	PRICE SENSITIVE	273.13KB	Share
OSL OncoSil FY21 half yearly review
18/01/21	PRICE SENSITIVE	245.86KB	Share
OSL Final Director's Interest Notice
18/12/20		220.98KB	Share
OSL Change of Director's Interest Notice
18/12/20		233.98KB	Share
OSL Change of Director's Interest Notice
18/12/20		233.95KB	Share
OSL Cancellation of shares under the Employee Share Plan
18/12/20		212.92KB	Share
OSL Termination of Mr Daniel Kenny as Chief Executive Officer
02/12/20	PRICE SENSITIVE	210.14KB	Share
OSL Change of Director's Interest Notice
05/11/20		233.98KB	Share
OSL Appendix 2A
05/11/20		394.89KB	Share
OSL OncoSil receives Swiss regulatory approval
05/11/20	PRICE SENSITIVE	220.13KB	Share
OSL Change of Director's Interest Notice
29/10/20		234.58KB	Share
OSL Change of Director's Interest Notice
27/10/20		232.99KB	Share
OSL OncoSil achieves first commercial sale
22/10/20	PRICE SENSITIVE	302.82KB	Share
OSL Appendix 4C - quarterly
21/10/20	PRICE SENSITIVE	506.86KB	Share
OSL Results of the OncoSil 2020 Annual General Meeting
20/10/20		294.36KB	Share
OSL Positive PanCO trial update on resected cohort
20/10/20	PRICE SENSITIVE	319.8KB	Share
OSL 2020 AGM CEO Presentation
20/10/20	PRICE SENSITIVE	984.59KB	Share
OSL 2020 AGM Chairman's Address
20/10/20		171.13KB	Share
OSL Receipt of $2.8m R&D Tax Incentive Refund
23/09/20	PRICE SENSITIVE	208.4KB	Share
OSL 2020 Notice of General Meeting & Proxy Form
18/09/20		1.02MB	Share
OSL Investor Update
28/08/20	PRICE SENSITIVE	1.34MB	Share
OSL Investor Update - Conference Call Notification
28/08/20		214.51KB	Share
OSL OncoSil receives Malaysian regulatory approval
28/08/20	PRICE SENSITIVE	264.36KB	Share
OSL Appendix 4G and Corporate Governance Statement
19/08/20		334.8KB	Share
OSL Preliminary Final Report - Appendix 4E Announcement
19/08/20	PRICE SENSITIVE	286.58KB	Share
OSL Appendix 4E and Annual Report
19/08/20	PRICE SENSITIVE	3.13MB	Share
OSL Clarification of June Quarter Appendix 4C
07/08/20		151.35KB	Share
OSL Appendix 4C - quarterly
30/07/20	PRICE SENSITIVE	507.9KB	Share
OSL HDE filing submitted in US for Bile Duct Cancer treatment
28/07/20	PRICE SENSITIVE	215.69KB	Share
OSL OncoSil presents clinical data at ESMO World Congress
03/07/20	PRICE SENSITIVE	538.69KB	Share
OSL OncoSil files for TGA registration
02/07/20	PRICE SENSITIVE	221.05KB	Share
OSL Change of Director's Interest Notice
30/06/20		123.55KB	Share
OSL Change of Director's Interest Notice
30/06/20		233.23KB	Share
OSL Cancellation of shares under the Employee Share Plan
30/06/20		204.79KB	Share
OSL OncoSil receives Singapore regulatory approval
01/06/20	PRICE SENSITIVE	258.23KB	Share
OSL Change of Directors Interest Notice
29/05/20		233.04KB	Share
OSL Change of Director's Interest Notice - Roger Aston
29/05/20		233.02KB	Share
OSL Change of Director's Interest Notice - Michael Bassett
29/05/20		233.81KB	Share
OSL Change of Director's Interest Notice - Martin Cross
29/05/20		232.94KB	Share
OSL Change in substantial holding - Daniel Kenny
29/05/20		233.04KB	Share
OSL Change of Director's Interest Notice - Chris Roberts
29/05/20		235.34KB	Share
OSL Appendix 3Y - Late Lodgement Notice - Roger Aston
29/05/20		571.4KB	Share
OSL Appendix 3Y - Late Lodgement Notice - Daniel Kenny
29/05/20		395.49KB	Share
OSL Appendix 2A
28/05/20		269.08KB	Share
OSL Ceasing to be a substantial holder
26/05/20		44.89KB	Share
OSL Entitlement Offer Results and Shortfall Notification
26/05/20	PRICE SENSITIVE	216.89KB	Share
OSL Ceasing to be a substantial holder
19/05/20		573.86KB	Share
OSL Becoming a substantial holder
13/05/20		335.63KB	Share
OSL Becoming a substantial holder
12/05/20		83.1KB	Share
OSL OncoSil Entitlement Offer Booklet
12/05/20	PRICE SENSITIVE	503.35KB	Share

REFRESH

First 2 3 4 5 6

(20min delay)
Last 1.3¢		Change 0.000(0.00%)		Mkt cap ! $49.19M

Open	High	Low	Value	Volume
1.3¢	1.3¢	1.3¢	$32	2.488K

Buyers (Bids)

No.	Vol.	Price($)
17	10151196	1.3¢

Sellers (Offers)

Price($)	Vol.	No.
1.4¢	4307472	9

View Market Depth

No.	Vol.	Price($)
17	10151196	0.013
15	9702101	0.012
19	8727036	0.011
16	11297430	0.010
12	4521222	0.009

Price($)	Vol.	No.
0.014	4307472	9
0.015	2205000	9
0.016	4392825	5
0.017	5155548	3
0.018	1532208	3

Last trade - 10.06am 02/10/2024 (20 minute delay)


Last 1.4¢		Change 0.000 ( 3.57 %)
Open	High	Low	Volume
1.4¢	1.4¢	1.4¢	127500
Last updated 11.27am 02/10/2024 ?

OSL (ASX) Chart

ONCOSIL MEDICAL LTD - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories